Blow to biosimilars in amended US health care act
A US Senate committee adopted an amendment to health care legislation on Monday night that will give 12 years of data exclusivity to innovative biologics
The amendment adopted by the Senate Health, Education, Labor and Pensions (HELP) Committee and sponsored by Senators Orrin Hatch, Kay Hagan and Mike Enzi - represents an important win for the biotechnology industry.
The Obama administration, the Federal Trade Commission...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.